Menarini

Showing: 1 - 3 of 3 RESULTS

Florence, Italy and New York (ots/PRNewswire) KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with …

WIdOmonitor: Caring relatives spend an average of 49 hours per week on...

Alternative Medicine

Menarini Group and Insilico Medicine sign exclusive global license agreement for …

by Ethel Purdy January 6, 2024January 6, 2024

Florence, Italy and New York (ots/PRNewswire) KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with …

Alternative Medicine

Menarini Group and Insilico Medicine enter into exclusive global license agreement for new KAT6 inhibitor for potential treatment of breast cancer and other oncology indications USA – Deutsch Italia – Italiano APAC – Traditional Chinese USA – español Latin America – español USA – English USA – English

by Ethel Purdy January 6, 2024January 6, 2024

KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with poor clinical outcomes in patients with …